ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 15 for:    (arctic OR alaska) AND (native OR tribal) AND (woman OR women OR female)
Previous Study | Return to List | Next Study

Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women (MAW)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01605643
Recruitment Status : Completed
First Posted : May 25, 2012
Last Update Posted : December 19, 2017
Sponsor:
Collaborators:
Alaska Native Tribal Health Consortium
University of California, San Francisco
University of Minnesota - Clinical and Translational Science Institute
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Christi Patten, Mayo Clinic

May 7, 2012
May 25, 2012
December 19, 2017
March 2012
June 2017   (Final data collection date for primary outcome measure)
NNAL [ Time Frame: delivery ]
Not Provided
Complete list of historical versions of study NCT01605643 on ClinicalTrials.gov Archive Site
cotinine [ Time Frame: participants will be followed during pregnancy until approximately week 40 gestation and Infants will be assessed at birth only ]
tobacco exposure measured during pregnancy and at delivery
Same as current
Not Provided
Not Provided
 
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women: Phase 1
Use of tobacco is very high among Alaska Native women. The investigators are conducting a three phase study. The first phase will examine biomarkers of tobacco exposure in pregnant women and their newborns. The second phase is a qualitative study to translate the biomarker findings into intervention messages. The third phase is a pilot of the biomarker feedback intervention compared with a control condition.
Developing effective tobacco cessation interventions during pregnancy for American Indian and Alaska Native people is a national priority and will contribute to the U.S. public health objective of reducing tobacco-related cancer health disparities. The proposed project builds on our successful partnership with the Alaska Native community and previous work with Alaska Native pregnant women. We propose to develop and test a novel biomarker feedback intervention relating cotinine levels in the urine of pregnant women with the woman and infant's likely exposure to the tobacco specific nitrosamine and carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK). This 5-year project will be conducted in three phases. In Phase 1 we will utilize a non-randomized, clinical observational trial to examine biomarkers of nicotine and carcinogen exposure (urine cotinine and total NNAL [a metabolite of NNK], respectively) among 150 maternal-infant pairs with assessments conducted during pregnancy and at delivery. In Phase 2, we will obtain qualitative feedback on the findings from Phase 1 through individual interviews conducted with 32 women who use tobacco to develop the biomarker feedback intervention messages. Phase 3 will consist of a formative evaluation of the biomarker feedback intervention with 80 pregnant women using a two-group randomized design to assess the intervention's feasibility and acceptability, and the biochemically confirmed abstinence rate at the end of pregnancy. All phases of the project will be guided by a Community Advisory Committee. Each phase is an important step to advance our understanding of the potential for biomarker feedback as a strategy to help Alaska Native pregnant women quit tobacco use. The potential reach of the intervention is significant from a public health perspective as over 600 tobacco users deliver each year at the Alaska Native Medical Center in Anchorage where the proposed project will take place. Developing effective interventions for tobacco cessation during pregnancy is important to reduce adverse health consequences for the mother and neonate and future risk of tobacco-caused cancers.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
urine and serum specimen samples collected from mother and infant pairs
Non-Probability Sample
Pregnant women will be recruited through prenatal care
  • Cancer
  • Tobacco Use
  • Pregnancy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
Same as current
December 2017
June 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

To be eligible the woman must:

  1. be Alaska Native,
  2. be aged 18 years or older,
  3. provide written informed consent,
  4. be currently pregnant (1st, 2nd or 3rd trimester), and
  5. plan to deliver at the ANMC. An additional inclusion criterion for current tobacco users is any use in the past 7 days. Our preliminary studies indicate that women may use more than one form of tobacco. To enhance feasibility of recruitment and generalizability, women will not be excluded if they use more than one form of tobacco. Instead, group composition will be based on the primary type of tobacco used. An additional inclusion criterion for non-tobacco users is no use of any form of tobacco in the last 6 months.

Exclusion Criteria:

  1. Women will be excluded if they have used nicotine replacement therapy (NRT) or have participated in a behavioral or pharmacological tobacco cessation program within the past 30 days.
  2. Alcohol and other drug use will not be an exclusionary criterion because the biomarkers are specific to tobacco exposure.
Sexes Eligible for Study: All
up to 50 Years   (Child, Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01605643
11-001144
U54CA153605 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Christi Patten, Mayo Clinic
Mayo Clinic
  • Alaska Native Tribal Health Consortium
  • University of California, San Francisco
  • University of Minnesota - Clinical and Translational Science Institute
  • National Cancer Institute (NCI)
Principal Investigator: Christi A Patten, PhD Mayo Clinic
Mayo Clinic
December 2017